Zepbound hair-shedding guide

Zepbound hair loss: current rates and clinician-review questions

Review current Zepbound hair-loss rates, female-versus-male trial data, weight-loss and nutrition questions, other causes, product identity, and clinician follow-up.

Educational guideUpdated August 13, 2026

A label-first check for hair loss during Zepbound care

Confirm the exact product: authentic FDA-approved Zepbound, its presentation and indication—not Mounjaro, compounded tirzepatide, or an unverified product.

Describe the pattern: diffuse shedding, thinning, breakage, smooth patches, scalp redness, pain, scaling, scarring, or eyebrow and body-hair changes are not interchangeable.

Record when it began, weight and appetite changes, food and protein intake, digestive symptoms, illness, stress, pregnancy or postpartum timing, and every medicine and supplement.

Ask whether history, examination, nutrition review, targeted labs, primary-care follow-up, or dermatology assessment fits the pattern.

Contact the prescriber before changing Zepbound; use prompt in-person care for rapidly worsening systemic, allergic, dehydration, or other serious symptoms.

Direct answer

Hair loss is a labeled adverse reaction with Zepbound, but the trial data do not predict what will happen to one person or prove the cause of a new shedding pattern. In two pooled adult weight-reduction trials, hair loss was reported in 5%, 4%, and 5% of participants in the three listed Zepbound groups versus 1% with placebo. The label says these reactions were associated with weight reduction and reports them more often in female than male participants. It does not provide a universal onset, duration, prevention method, or regrowth timeline. Contact the prescriber for new, persistent, severe, patchy, painful, or concerning hair loss—especially with scalp inflammation, poor intake, rapid weight change, fatigue, menstrual changes, or another new symptom. Do not stop, restart, change, or add treatment or supplements from a generic online answer.

Current label evidence

Zepbound reports hair loss in product- and trial-specific groups

The current Eli Lilly Zepbound prescribing information was revised April 22, 2026. In two pooled placebo-controlled adult weight-reduction trials, the adverse-reaction table reports hair loss in 1% of placebo participants and 5%, 4%, and 5% of participants receiving the three listed Zepbound groups. The label separately says hair-loss adverse reactions in Zepbound-treated participants were associated with weight reduction. These data show a reported trial signal; they do not identify the cause, pattern, severity, onset, duration, or expected recovery for an individual.

Keep the percentages tied to the pooled adult weight-reduction trials; do not add dose-group rates together or treat them as a personal forecast.
Association with weight reduction does not prove that every case was caused by the medicine, the amount of weight lost, nutrition, or one specific mechanism.
The current label does not provide a hair-loss prevention protocol, supplement regimen, safe waiting period, or guaranteed regrowth timeline.

Female and male trial data

The pooled label analysis reports an important sex difference

In the pooled trials, the label reports hair loss more frequently in female than male participants: 7.1% versus 0.5% in Zepbound-treated participants, and 1.3% versus 0% in placebo participants. No Zepbound-treated participant and one placebo participant discontinued study treatment due to hair loss. This pooled female-versus-male analysis is different from the separate dose-group table and should not be used to predict an individual risk or to minimize a distressing symptom.

Do not combine the sex-specific percentages with the dose-group percentages or imply that separate analyses are one head-to-head comparison.
Trial discontinuation data do not establish that every episode was mild, temporary, cosmetically unimportant, or safe to ignore.
Pregnancy, postpartum changes, menopause, hormonal conditions, and other sex-specific history may still require patient-specific review.

Pattern and other possible causes

Diffuse shedding, patches, breakage, and inflamed scalp findings need different assessments

Hair loss has many possible contributors. Major weight change, low protein or overall food intake, thyroid disease, iron or other nutrient concerns, illness, surgery, stress, pregnancy or postpartum changes, hormonal conditions, genetics, scalp disease, and other medicines can overlap with Zepbound care. MedlinePlus notes that thyroid problems, medicines, stress, low-protein diets, and poor nutrition can contribute to hair loss. The American Academy of Dermatology also describes thyroid disease and insufficient iron, protein, zinc, or biotin among possible causes. An article cannot determine the cause from timing alone.

Report smooth bald patches, scalp pain, redness, scale, drainage, scarring, broken hairs, eyebrow loss, rash, or nail changes instead of describing every pattern as routine shedding.
Share vomiting, diarrhea, constipation, markedly reduced appetite, trouble maintaining fluids or food, rapid weight change, fatigue, dizziness, fever, bleeding, and menstrual changes.
List prescriptions, OTC medicines, hormones, vitamins, minerals, protein products, hair supplements, alcohol, and other substances before adding another product.

Evaluation and treatment decisions

The next step is cause-focused review—not an automatic dose change or supplement bundle

The responsible clinician can review the timeline, weight-loss pace, intake, digestive symptoms, medication list, pregnancy or postpartum context, thyroid and iron history, scalp findings, and other symptoms. Examination, targeted laboratory testing, primary-care follow-up, or dermatology referral may be appropriate depending on the pattern. Testing is not automatically identical for every patient, and a supplement should not be started merely because it appears in a hair-loss advertisement.

Do not skip, repeat, split, stop, restart, increase, decrease, or switch Zepbound based on generic online hair-loss advice.
Do not assume biotin, iron, zinc, vitamin A, selenium, protein powders, topical medicines, or prescription hair treatments are necessary or safe without reviewing the cause, interactions, contraindications, and testing needs.
Seek prompt assessment when hair loss is abrupt, severe, patchy, painful, scarring, accompanied by scalp inflammation, or paired with significant systemic symptoms.

Product identity and compounded care

Zepbound trial rates do not establish risk for Mounjaro or compounded tirzepatide

Zepbound is an FDA-approved Eli Lilly tirzepatide injection with product-specific adult chronic-weight-management and obstructive-sleep-apnea indications. Current labeling includes single-dose pens and vials, multi-dose vials, and single-patient-use KwikPens. Mounjaro contains tirzepatide but has different indications, populations, presentations, and adverse-reaction evidence. A patient-specific compounded tirzepatide preparation is not FDA-approved Zepbound or Mounjaro and is not an FDA-approved generic tirzepatide finished product. It may differ in concentration, inactive ingredients, container, supplies, labeling, storage, and beyond-use date.

Bring the exact product name, presentation, prescription and pharmacy label, refill or lot details, storage history, treatment timeline, and a photo of the package to the review.
Do not transfer Zepbound hair-loss percentages to Mounjaro, a compounded vial, an additive combination, a research-use product, or an unlabeled injection.
Avoid no-prescription sellers, counterfeit pens, unlabeled products, research-use vials, and claims that shedding proves potency or faster weight loss.

Patient safety checklist

Questions to ask about hair loss during Zepbound treatment

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Is the product authentic FDA-approved Zepbound, and which presentation, indication, treatment timeline, and current label apply?

✓

Is the pattern diffuse shedding, thinning, breakage, smooth patches, scalp inflammation, pain, scaling, scarring, or hair loss elsewhere?

✓

When did it start, is it worsening, and how does the timing relate to treatment, weight change, appetite, digestive symptoms, illness, surgery, stress, or another medicine?

✓

Am I maintaining enough food and protein for my individualized plan, and do vomiting, diarrhea, constipation, poor intake, dehydration, or rapid weight change need review?

✓

Do thyroid or iron history, menstrual changes, pregnancy or postpartum timing, hormones, recent illness, bleeding, fatigue, or other symptoms change the assessment?

✓

Could another prescription, OTC product, supplement, vitamin, mineral, or hair treatment contribute or interact?

✓

Would examination, targeted labs, primary-care follow-up, or dermatology assessment fit this pattern?

✓

Who should decide whether Zepbound continues or changes, and which symptoms need prompt in-person care?

FAQs

Short answers for patients

Can Zepbound cause hair loss?

Hair loss is a labeled adverse reaction with Zepbound. In two pooled adult weight-reduction trials, it was reported in 5%, 4%, and 5% of participants in the three listed Zepbound groups versus 1% with placebo. The label says hair-loss reactions were associated with weight reduction, but these group-level data do not prove the cause of one person’s shedding.

Is hair loss more common in women taking Zepbound?

The pooled label analysis reports hair loss in 7.1% of female and 0.5% of male Zepbound-treated participants, versus 1.3% of female and 0% of male placebo participants. These trial-group percentages are not an individual prediction and do not explain the cause, severity, pattern, or duration.

How long does Zepbound hair loss last?

The current Zepbound label does not provide a universal onset, duration, or regrowth timeline. Contact the prescriber for new, persistent, severe, patchy, painful, or concerning hair loss so the pattern, weight change, nutrition, other medicines, scalp findings, and possible medical causes can be reviewed.

Should I stop Zepbound because my hair is shedding?

Do not skip, repeat, stop, restart, split, or change Zepbound from a generic online answer. Contact the responsible prescriber with the exact product and symptom timeline before the next treatment decision. Prompt in-person assessment may be needed for severe, patchy, painful, inflamed, scarring, or rapidly worsening hair loss or significant systemic symptoms.

Do vitamins or supplements prevent Zepbound hair loss?

The current label does not establish a prevention supplement. Hair loss can have multiple causes, and unnecessary supplements may add side effects, interactions, or excessive nutrient exposure. A clinician can review intake, history, medicines, examination findings, and whether targeted testing is appropriate before recommending a product.

Do Zepbound hair-loss rates apply to compounded tirzepatide?

No. A patient-specific compounded preparation is not an FDA-approved Zepbound finished product and may differ in concentration, inactive ingredients, presentation, labeling, storage, and beyond-use date. Zepbound trial percentages do not establish its hair-loss incidence, expected timeline, or quality.

When should hair loss during Zepbound care be checked promptly?

Request prompt clinical review for sudden, severe, rapidly worsening, patchy, painful, inflamed, or scarring hair loss; scalp drainage; eyebrow or body-hair changes; or shedding with poor intake, dehydration, marked weakness, fainting, fever, bleeding, menstrual changes, or another significant symptom.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Current ZEPBOUND prescribing information — revised April 22, 2026 DailyMed API: Manufacturer ZEPBOUND structured product label MedlinePlus: Hair loss MedlinePlus: Tirzepatide injection drug information — revised February 15, 2026 American Academy of Dermatology: Causes of hair loss FDA: Compounding and the FDA — Questions and Answers Peptide12: Zepbound Peptide12: Compounded tirzepatide injection Peptide12: Zepbound injection side effects Peptide12: Zepbound and hypothyroidism Peptide12: GLP-1 protein intake Peptide12: GLP-1 hair loss overview Peptide12: Zepbound pen not working Peptide12: When to message your clinician Peptide12: How online peptide therapy works